Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.52 |
| ▸ | ALB | P02768 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200313 | 0.94 | TTR (0.52) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL16951758 | 0.87 | TTR (0.43) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL19062532 | 0.84 | TTR (0.44) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL16950941 | 0.84 | TTR (0.44) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL1979138 | 0.83 | TTR (0.40) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL60145 | 0.83 | TTR (0.50) | TTRALBMEN1KMT2AVCAM1 | |
| SCHEMBL254589 | 0.82 | TTR (0.43) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL12514204 | 0.82 | TTR (0.43) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL1883717 | 0.82 | TTR (0.54) | TTRALBMEN1KMT2AMAOB | |
| SCHEMBL505159 | 0.82 | MEN1 (0.43) | TTRALBMEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115772139-A | 2, 3-benzophenothiazine derivative, preparation method and application | 南京邮电大学 | 2023-03-10 | — | — | CN | claimed |
| CN-113845491-A | Benzophenothiazine derivatives and process for their preparation | 南京邮电大学 | 2021-12-28 | — | — | CN | claimed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | SOLEY THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4619387-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025135309-A1 | ORGANIC LIGHT-EMITTING COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 솔루스첨단소재 주식회사 | 2025-06-26 | — | — | WO | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-120157679-A | Dendritic luminescent material based on space charge transfer, preparation method and application | 长春理工大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-111196780-B | Organic electroluminescent device and compound for organic electroluminescent device | 三星显示有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-1349516-A | Cyclothiocarbamate derivatives as progesterone receptor modulators | AMERICAN HOME PROD (US) | 2002-05-15 | — | — | CN | disclosed |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2002-04-25 | — | — | US | disclosed |
| EP-1173210-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1173426-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| CN-1284074-A | Novel compounds | ASTRA ZENECA BRITISH LTD (GB) | 2001-02-14 | — | — | CN | disclosed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066164-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-1037889-A1 | NOVEL COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999029686-A1 | NOVEL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | MKI67, BCL2, CCAR2 | TTR 3982/4885ALB 4493/4885MEN1 1555/4885 |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | NCOR1, NOP56, NCOR2 | TTR 3135/4885ALB 3875/4885MEN1 2848/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | TTR 122/4885ALB 1330/4885MEN1 2120/4885 |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C1, NR5A1, CNR1 | TTR 3970/4885ALB 4428/4885MEN1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.